PARIS – September 9, 2021 – The Phase 3 PEGASUS trial evaluating rilzabrutinib to treat pemphigus, a rare autoimmune skin condition, did not meet its primary or key secondary endpoints.

When combined with low-dose corticosteroids, a Bruton tyrosine kinase (BTK) inhibitor rilzabrutinib did not result in complete remission (CR) in patients with newly diagnosed or relapsing pemphigus.

Please provide your email address to receive an email when new articles are posted on . Research shows nearly 20% of patients with pemphigus experience relapse. An additional dose of rituximab in ...

Paraneoplastic pemphigus is typically a side effect of a cancerous tumor and can cause mouth pain and oral sores. It can be aggressive and should be diagnosed and treated as soon as possible.

Scientists at Scripps Research have reported success in initial tests of a new, nanotech-based strategy against autoimmune diseases. The National Institutes of Health has begun a clinical trial to ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...